Notably, patient 1 was characterized by an MGMT-methylated, hypermethylated, and potentially hypermutated glioblastoma, and previously showed long-term response to dendritic cell (DC) immunotherapy in the DENDR1 trial (NCT04801147).75 This evidence concerns the gene MGMT and glioblastoma.